We narrowed to 3,489 results for: psin

#105677-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Aug. 17, 2018

Academic Institutions and Nonprofits only

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#105678-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Sept. 24, 2020

Academic Institutions and Nonprofits only

#105677-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#205997-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn_WiChR_TS_mScarlet_ER (#205997). In addition to the viral particles, you will also receive purified pAAV_hSyn_WiChR_TS_mScarlet_ER plasmid DNA. hSyn-driven K+ selective channelrhodopsin for optogenetic inhibition of neurons. These AAV preparations are suitable purity for injection into animals.

Peter Hegemann, Johannes Vierock

Vierock et al Sci Adv. 2022 Nov 16:eadd7729.

July 30, 2025

Academic Institutions and Nonprofits only

#105669-AAV1

Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 17, 2018

Academic Institutions and Nonprofits only

#105669-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only

#139505-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#139504-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

April 10, 2024

Academic Institutions and Nonprofits only

#139504-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Nov. 13, 2025

Academic Institutions and Nonprofits only

#125713-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

Sept. 20, 2019

Academic Institutions and Nonprofits only

#125713-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

Sept. 13, 2021

Academic Institutions and Nonprofits only

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#20071-AAV9

Ready-to-use AAV9 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

March 15, 2018

Academic Institutions and Nonprofits only